# 1. Financial Performance ## A. Key Figures * **Total Revenues from Operations:** **₹7,168 Cr** Q3 FY26 (+24%) · **₹5,768 Cr** Q3 FY25 * Gross Margin: 73.5% Q3 FY26 (+420 bps YoY) * EBITDA Margin: 31.1% Q3 FY26 (+681 bps YoY) · 27%–28% expected full-year FY26 * EBITDA (9M): ₹5,988 Cr (+50% YoY) · Margin: 29.8% (+580 bps YoY) * **Net Cash:** **₹2,879 Cr** (as of 31 Dec) vs. **₹310 Cr** (as of 31 Mar 2025) ## B. Revenue Growth * **Sustained Momentum:** Achieved 14th consecutive quarter of YoY revenue growth, with Q3 marking a new all-time high in sales performance. * **PLI Impact:** Other operating income declined significantly due to lower export benefits under the PLI scheme, creating a headwind versus prior periods. ## C. Gross Margins * **Margin Expansion Drivers:** Gross margin improvement driven by favorable product mix, reduced exposure to in-licensed and loss-of-exclusivity products in India, and cost efficiencies. * **Tax Outlook:** Full-year effective tax rate projected at **21%–22%**, a notable increase from 9MFY26’s 4%. ## D. EBITDA Margins * **Record Profitability:** EBITDA margin reached a record high, reflecting strong operating leverage and disciplined cost management despite rising employee and manufacturing expenses. * **R&D & PLI Pressure:** Q4 margins expected to moderate due to higher R&D outlays and diminished PLI-related income, even as core business remains robust. * **Licensing Impact:** Upfront payments amortized over time; per-unit fees will reduce operating profit, with settlement acknowledged to affect profitability but preserve EBITDA-level attractiveness. ## E. Cash Flow * **Strong Cash Generation:** Net cash balance surged on enhanced operating cash flows, despite working capital expansion to **101 days**, indicating scalable operational execution. --- # 2. Segment & Geography Mix ## A. Key Figures * **US Sales:** **$350 Mn** (+46% YoY, +11% QoQ CC) * India Revenue Growth: 5.6% YoY · Core Rx +10.9% YoY (Q3) * India Volume Growth: 5.6% (9M) · 6.5% (Q3) * **Emerging Markets Growth:** **42% YoY** · **Brazil +99% YoY LC** * **Other Developed Markets Growth:** **11% YoY** · **INR 812 Cr** revenue * **Chronic Portfolio Share (India):** **67%** of Rx mix ## B. US Business * **Record US Performance:** Strongest-ever quarterly sales driven by successful launches of **Tolvaptan** (only generic) and **Risperdal Consta®** with CGT exclusivity from Nanomi platform. * **Growth Drivers:** New product momentum and seasonal tailwinds in **Albuterol, Tiotropium, and Oseltamivir** outweighed low single-digit price erosion. * **Sustained Contribution:** **Tolvaptan** (35% market share) and **Mirabegron** expected to remain key revenue contributors through FY27–FY28. * **Future Growth Levers:** Strategic focus on building **biosimilars and injectables** institutional business as next-phase drivers over 3–5 years. ## C. India Rx * **Resilient Core Growth:** Prescription business expanded at **9% YoY in Q3**, with volume as primary driver, reflecting limited reliance on pricing. * **Portfolio Shift:** Chronic therapies now represent **67% of portfolio**, enhancing stability and profitability, while in-licensed product share declined to **6%**. * **Growth Enablers:** Expansion supported by **>11,000 salesforce**, recent addition of **900 MRs**, and resolution of insulin supply issues. * **Innovation Pipeline:** Upcoming launches including **Semaglutide**, backed by dedicated **200-MR team**, to sustain momentum over next several years. * **Outperformance Target:** Aims to grow **2–3x faster than IPM**, targeting **double-digit CAGR** vs. market growth of **7–8%**. ## D. Emerging Markets * **Broad-Based Momentum:** Double-digit growth across LATAM, Europe, and Asia, led by **Brazil (+99% LC)** on back of **Dapagliflozin** commercialization. * **Brazil Surge:** Near-doubling of market performance driven by strong product uptake and expanding portfolio depth. * **Offsetting Weakness:** Robust performance in **Mexico, Philippines, and Brazil** compensated for softer results in South Africa. ## E. Other Developed Markets * **Stable Expansion:** Region grew **11% YoY**, contributing **11% of total sales**, with growth underpinned by complex products and pipeline momentum. * **Strategic Enhancement:** **VISUfarma acquisition** expected to close this quarter, boosting footprint in Europe and future growth potential. --- # 3. Product & Therapy Performance ## A. Key Figures * Therapy Growth: Respiratory 1.6x IPM · Cardiovascular 1.3x IPM (9M) * **Market Opportunity:** Semaglutide generic launch – **INR 1,500 Cr** Year 1 · Lupin’s projected take: **INR 50–60 Cr** * **Biosimilars Revenue Potential:** **~USD 100 Mn** over 2–3 years from key pipeline assets * **Injectables Sales Target:** **>USD 100 Mn** within 3 years * **Mirabegron Market Share:** **40%** of total molecule market (generic share shared with Zydus) * **Chronic Therapy Market Share:** Expanded to **67%** ## B. Respiratory Portfolio * **Outperformance Confirmed:** Respiratory and cardiovascular therapies significantly outpaced market growth, reflecting strong commercial execution and category leadership. * **Strategic Specialty Focus:** Respiratory remains a cornerstone of the company’s three-pillar specialty strategy, alongside neurology and ophthalmology, enabling cross-portfolio commercial leverage. * **Breo Ellipta Pipeline Update:** Material progress expected toward filing within CY24, though initial timeline delayed; remains a key near-term catalyst. ## C. Diabetes & Obesity * **Day-One Launch Readiness:** Company positioned for immediate entry into India’s Semaglutide market, leveraging its established cardio-metabolic footprint and multi-specialist engagement. * **Responsible Commercialization Stance:** Emphasis on ethical distribution and patient support over aggressive volume capture, with sufficient supply to maintain equitable market share. * **Chronic Therapy Strength:** Market share expansion to 67% underscores sustained demand and effective penetration in core therapy areas. * **Portfolio Expansion:** Dual focus on high-value specialty projects and increased project volume, including oral Semaglutide development alongside injectable launch. ## D. Biosimilars Launch * **E. S. Market Entry Achieved:** First U.S. biosimilar approval secured for Pegfilgrastim, with imminent launch and a robust pipeline (Ranibizumab, Aflibercept, Etanercept, Mepolizumab) through FY30. * **Scaled Advantage:** Positioned as the only fully integrated, India-based biosimilars player, providing structural cost advantages and margin resilience despite pricing pressure. * **Attractive Competitive Landscape:** Biosimilars seen as superior to small molecule generics due to lower competition, with only a few global players operating at scale. * **Xywav First-to-File Leverage:** Exclusive tentative approval in hand; FY29 launch contingent on litigation outcome. ## E. Injectables Pipeline * **Multi-Year Growth Vector:** Injectables portfolio, including Glucagon, Liraglutide, and Risperdal Consta®, expected to exceed **USD 100 Mn** in sales within three years. * **Diversified Launch Cadence:** Growth supported by biosimilars, 505(b)(2) filings, and new product approvals, signaling broad-based momentum beyond generics. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **R&D Spend:** **₹535 Cr** Q3FY26 (7.5% of sales) · **₹1,555 Cr** 9MFY26 (7.7% of sales) ## B. Complex Generics * **Strategic R&D Shift:** Increased investment in high-barrier platforms—**Respiratory, Complex Injectables, and Biosimilars**—with over **50 active pipeline products**, while de-prioritizing traditional oral solids. * **IP Leadership:** Tolvaptan program advanced with resolution of IP challenges, potentially positioning Lupin ahead of delayed competitors. * **Spending Trajectory:** Absolute R&D outlays expected to rise further, though percentage of sales may stabilize with revenue scale. ## C. 505(b)(2) Programs * **New Growth Vector:** First 505(b)(2) launch expected in **FY27**, focused on injectables, with potential to become a **material contributor** through in-house development and in-licensing. * **Portfolio Focus:** Emphasis on **long-acting injectables, green propellant products**, and **value-added medicines** to drive differentiation. ## D. Biosimilar Development * **US Market Entry:** Achieved **first biosimilar approval in the US (Pegfilgrastim)** following successful FDA inspection of Pune biologics facility—a key regulatory milestone. * **Selective Pipeline Strategy:** Prioritizing first-wave opportunities with technological or strategic advantage, including **Nexplanon® drug-device combination**, with filing planned for **FY28**. ## E. AI Integration * **Enterprise-Wide AI Rollout:** AI adoption expanding beyond sales into core functions (manufacturing, quality, finance); **multiple pilots to be implemented in 9–12 months**. * **Data Foundation:** Focus on unifying fragmented data systems via architectural overhaul to enable scalable AI integration across the organization. ## F. Pipeline Highlights * **Dual-Track Dalbavancin:** Filed both generic and **505(b)(2)** versions, alongside key injectables **Eribulin** and **Iron Sucrose**, signaling strategic depth in complex portfolios. --- # 5. M&A & Strategic Partnerships ## A. Key Figures * Strategic Borrowing Capacity: USD 1.5–1.6 Bn additional capacity * **Target Deal Size:** **USD 250–300 Mn** preferred range for specialty assets * **VISUfarma Annual Revenue:** **>EUR 60 Mn** (euro-denominated) * **Licensing Outgo for Mirabegron:** **$75 Mn** lump sum, separate from per-unit fees ## B. VISUfarma Acquisition * **Imminent Close:** Acquisition expected to close in the coming weeks, with consolidation beginning next quarter. * **Upside to Revenue:** VISUfarma’s revenue outlook revised upward to exceed **EUR 60 Mn**, reflecting stronger-than-expected commercial performance. * **Deal Flexibility:** Company remains open to larger deals if strategic fit justifies moving beyond the **USD 250–300 Mn** sweet spot. * **Stage-Agnostic Strategy:** Evaluating both commercial-stage and clinical-stage assets, including those requiring further investment pre-launch. ## C. Licensing & Commercialization * **D. S. Biosimilar Launch:** Pegfilgrastim to launch in the U.S. via exclusive agreement with **Valorum** before end of Q3 FY26. * **China Partnership:** Tiotropium collaboration with a Chinese firm represents a **meaningful international opportunity**, though financial details remain undisclosed. * **Distributor Strength:** Partnerships with **McKesson and AmerisourceBergen** enhance U.S. biosimilar reach and commercial readiness. ## D. In-Licensing & Portfolio Expansion * **Strategic In-Licensing:** Partnership with **Gan & Lee** for **Bofanglutide**, a novel **fortnightly GLP-1 agonist**, bolsters diabetes and obesity pipeline in India. * **Development-Stage Focus:** Preference for late-stage assets (Phase III or post-Phase II), though open to commercialized products when available. * **Spending Discipline:** Defined investment thresholds for adjacencies ensure capital alignment with strategic objectives. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Mirabegron Payout:** **$15 Mn** upfront provision · **$75 Mn** future expense (through Sep 2027) ## B. Patent Expiries * **Liability Recognition:** $90 Mn Mirabegron settlement structured with immediate $15 Mn charge and **$75 Mn to be expensed over time**, reflecting ongoing market participation. * **Exclusivity Timeline:** Mirabegron exclusivity expected to last until **September 2027**, aligned with peer generic settlements despite longer Orange Book patent. * **Competitive Barriers:** Manufacturing complexity for Tolvaptan and **30-month stay for competitors (into 2027)** may delay generic entry, supporting staggered market competition. ## C. PBM Dynamics * **Regulatory Neutrality:** Recent U.S. PBM reforms, including Trump Rx, seen as **neutral for generics**, with no material pricing impact or shift in rebate dynamics. * **Biosimilar Opportunity:** PBM-driven private label biosimilars (e.g., Cordavis’ Humira®) represent a **strategic opening for market share capture**, not a threat. * **Evolving Access Model:** Shifting PBM behavior—**declining blockades and rising partnerships**—improves biosimilar market access and commercialization pathways. ## D. FDA Compliance * **Regulatory Progress:** Nagpur Unit-1 received **NAI (zero observations)**; EIRs issued for Nagpur Unit-2 injectables and Aurangabad facility, underscoring sustained focus on global compliance. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Margin Guidance:** **24%–25%** for FY27 ## B. Margin Forecast * **Margin Resilience:** EBITDA margins expected to hold in the **24%–25% range** despite competitive pressures, underpinned by gross margin preservation and cost discipline. * **R&D Prioritization:** Margin guidance reflects **planned increase in R&D spending** to advance multiple innovation initiatives. ## C. Revenue Trajectory * **Sustained Scale:** Company positioned to maintain **billion-plus revenue level** on strength of biosimilars, respiratory/injectables, and **first-to-file opportunities**. * **Growth Catalysts:** Top-line momentum to continue via **Mirabegron** and **Tolvaptan** performance, **Semaglutide potential**, new launches, and **Emerging Markets expansion**. * **Normalization Ahead:** Seasonal uplift in U.S. sales expected to **moderate over next two quarters**. ## D. Launch Pipeline * **Complex Product Ambition:** Lupin aims to **double share of complex products** in U.S. portfolio, supported by organic development and targeted M&A. * **Pegfilgrastim Launch Imminent:** Biosimilar launch expected **this quarter**, with meaningful revenue ramp anticipated in **next fiscal year**, aided by favorable payer dynamics. * **Strategic Certainty:** **Mirabegron settlement** removes litigation risk through **September 2027**, ensuring uninterrupted sales despite royalty-bearing market entry by others. * **Future-Ready Growth:** Leadership emphasizes **innovation**, **technology investments (including AI)**, and **specialty focus** as pillars of long-term resilience and growth.